Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma
Executive Summary
Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.
You may also be interested in...
Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Genentech/Novartis' Xolair allergic asthma patient population should not be restricted except by age, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended May 15
Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Genentech/Novartis' Xolair allergic asthma patient population should not be restricted except by age, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended May 15
Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
A "safety signal" detected during Genentech's Phase III trial of Tarceva (erlotinib) for first-line combination therapy in non-small cell lung cancer will not impact the rest of the agent's development program, the company said April 9